Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Casali, P G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Soft tissue sarcoma; Target therapy

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CRIZOTINIB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TRABECTEDIN;

ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLEAR CELL SARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFICACY; DRUG MEGADOSE; HISTOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MOLECULARLY TARGETED THERAPY; PERIVASCULAR EPITHELIOID CELL TUMOR; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; SYNOVIAL SARCOMA; TREATMENT RESPONSE; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMANGIOSARCOMA; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA; LIPOSARCOMA, MYXOID; SARCOMA; SOFT TISSUE NEOPLASMS; SOLITARY FIBROUS TUMORS;

EID: 84866757432     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds349     Document Type: Article

References (31)

1. Lorigan P, Verweij J, Papai Z et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25: 3144-3150.
2. Garcia del Muro X, Lopez-Pousa A, Martin J et al. Spanish Group for Research on Sarcomas. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005; 104: 1706-1712.
3. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-1285.
4. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
5. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
6. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-1608.
7. Meazza C, Casanova M, Luksch R et al. Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: feasibility and efficacy in refractory pediatric sarcoma. Pediatr Blood Cancer 2010; 55: 617-620.
8. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-5274.
9. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25: 2755-2763.
10. Duffaud F, Pautier P, Bui Nguyen B et al. A pooled analysis of the final results of the two randomized Phase II studies comparing gemcitabine (G) vs gemcitabine + docetaxel (G+D) in patients (pts) with metastatic/relapsed leiomyosarcoma (LMS). Ann Oncol 2010; 21 (Suppl. 8): viii408.
11. Stacchiotti S, Palassini E, Sanfilippo R et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 2012; 23: 501-508.
12. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
13. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23: 576-584.
14. Forni C, Minuzzo M, Virdis E et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009; 8: 449-457.
15. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602.
16. van der Graaf WTA, Blay J-Y, Chawla SP et al. Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886.
17. Chawla SP, Blay J-Y, Ray-Coquard IL et al. Results of the phase III, placebocontrolled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011; 29(suppl) (abstr. 10005).
18. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-3132.
19. McCormack FX, Inoue Y, Moss J et al. National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606.
20. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010; 28: 835-840.
21. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
22. George S, Merriam P, Maki RG et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27: 3154-3160.
23. Stacchiotti S, Negri T, Zaffaroni N et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 2011; 22: 1682-1690.
24. Stacchiotti S, Negri T, Palassini E et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther 2010; 9: 1286-1297.
25. Stacchiotti S, Grosso F, Negri T et al. Tumor response to sunitinib malate observed in clear-cell sarcoma. Ann Oncol 2010; 21: 1130-1131.
26. Kummar S, Strassberger A, Monks A et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). J Clin Oncol 2011; 29(suppl) (abstr. 10001).
27. Park MS, Patel SR, Ludwig JA et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 2011; 117: 4939-4947.
28. Rutkowski P, Van Glabbeke M, Rankin CJ et al. European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 28: 1772-1779.
29. Stacchiotti S, Pedeutour F, Negri T et al. Dermatofibrosarcoma protuberansderived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011; 129: 1761-1772.
30. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363: 1727-1733.
31. Casali PG. Do rare cancers deserve specific strategies for cancer research? Lancet Oncol 2010; 11: 506-507.